| Name | Title | Contact Details |
|---|
Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.
Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease.
Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.